Journal
CHEMICAL COMMUNICATIONS
Volume 50, Issue 56, Pages 7427-7430Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4cc00419a
Keywords
-
Categories
Funding
- National Basic Research Program of China (973 Program) [2012CB932502]
- National Science Foundation of China [U1332210, 21171156, 51390482, 51125012]
Ask authors/readers for more resources
Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells. Asplatin is highly accumulated in cancer cells and is activated upon the reduction by ascorbic acid.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
